Stockscreener 앱 받기
26.69
0.96%
-0.26
시간 외 거래:
28.02
1.33
+4.98%
전일 마감가:
$26.95
열려 있는:
$26.91
하루 거래량:
126.52K
Relative Volume:
2.24
시가총액:
$934.11M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-10.94%
1개월 성능:
+4.79%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$26.28
$27.27
1주일 범위
$26.28
$30.40
52주 변동 폭
$22.51
$31.13
Oruka Therapeutics Inc Stock (ORKA) Company Profile
명칭
Oruka Therapeutics Inc
전화
(720) 940-2200
주소
10170 CHURCH RANCH WAY, WESTMINSTER
Oruka Therapeutics Inc 주식(ORKA)의 최신 뉴스
Oruka Therapeutics to Present at Multiple November Investor Conferences - StockTitan
Oruka stock draws buy rating at Stifel (NASDAQ:ORKA) - Seeking Alpha
Oruka Therapeutics shares gain buy rating as H.C. Wainwright sees strong future in psoriasis treatment - Investing.com Canada
Oruka Therapeutics Adjusts Executive Severance Agreements - TipRanks
Oruka Therapeutics (NASDAQ:ORKA) Stock Quotes, Forecast and News Summary - Benzinga
Oruka shares rise as TD Cowen maintains buy on drug potential - Investing.com Canada
Oruka Therapeutics reveals promising preclinical data for psoriasis treatment - Investing.com
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of ... - The Bakersfield Californian
Oruka Therapeutics Announces Preclinical Data for ORKA-001 - GlobeNewswire
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress - StockTitan
Ordell Minerals Advances Gold Prospects with Phase 2 Drilling - TipRanks
Orkla ASA (OTCMKTS:ORKLY) Sets New 1-Year High at $9.47 - Defense World
Orgenesis announces reverse stock split to meet Nasdaq requirements By Investing.com - Investing.com Australia
Orora (OTCMKTS:ORRYY) Shares Up 32.6% - Defense World
Why Orgenesis (ORGS) Stock Is Down 23% Today - Benzinga
‘Omni Loop’ takes a bit too much on its plate - Daily Trojan Online
Private Auckland hospital doubles in size: New $3m robot, extra beds, surgical expansion - New Zealand Herald
Organon: A Surprising Deal (NYSE:OGN) - Seeking Alpha
‘Omni Loop’ (2024) Movie ReviewNothing New | MOVIESR.NET - Midgard Times
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $41.25 Average PT from Analysts - Defense World
Halozyme's ENHANZE® (HALO) Technology Empowers OCREVUS ZUNOVO™: A New Era in MS Treatment - BP Journal
Oruka Therapeutics (NASDAQ:ORKA) Coverage Initiated at Leerink Partners - Defense World
Research Analysts Offer Predictions for Oruka Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:ORKA) - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Stock Rating Upgraded by Leerink Partnrs - Defense World
Ocugen Inc [OCGN] Stock bought by Insider RAMESH KUMAR for $0.15 million - Knox Daily
‘Omni Loop’ Review: Sci-Fi Indie Offers Some Ham-Fisted Heart - Observer
Lifesci Capital Initiates Coverage on Oruka Therapeutics (NASDAQ:ORKA) - Defense World
TD Cowen Initiates Coverage on Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Leerink Partners starts drug developer Oruka with 'outperform' - XM
Oruka Therapeutics initiated with an Outperform at Leerink - TipRanks
Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections - Benzinga
Roche scores first, with FDA approval of Ocrevus Zunovo for MS - The Pharma Letter
Analysts Issue Forecasts for Oruka Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:ORKA) - Defense World
FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech - Pharmaceutical Technology
Oruka Therapeutics (NASDAQ:ORKA) Coverage Initiated at Jefferies Financial Group - Defense World
Oruka Therapeutics Secures $200M to Advance Skin Disease Treatments - TipRanks
FDA approves new multiple sclerosis treatment OCREVUS ZUNOVO By Investing.com - Investing.com Australia
Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis - PR Newswire
FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug - STAT
Oruka to advance psoriasis programs into clinic next year - BioWorld Online
Jefferies starts Oruka Therapeutics with buy, $40 target - Investing.com UK
Biotech firm enters $200M agreement - The Business Journals
Oruka Therapeutics secures $200 million in PIPE financing By Investing.com - Investing.com Canada
Oruka Therapeutics sets clinical trial dates for skin disease drugs - Investing.com
Oruka Therapeutics secures $200 million in PIPE financing - Investing.com
Oruka Therapeutics Announces $200 Million Private Placement - GlobeNewswire
Oruka Therapeutics Announces Accelerated Clinical Timelines - GlobeNewswire
Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19 - StockTitan
Oruka Therapeutics (NASDAQ:ORKA) Upgraded at Wedbush - Defense World
Arca Biopharma, Oruka Therapeutics merger complete - Boulder Daily Camera
Oruka Therapeutics (NASDAQ:ORKA) Receives New Coverage from Analysts at Wedbush - Defense World
Oruka Therapeutics Inc (ORKA) 재무 분석
Oruka Therapeutics Inc (ORKA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Oruka Therapeutics Inc 주식 (ORKA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 24 '24 |
Buy |
3.20 |
189,856 |
606,873 |
2,081,168 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 25 '24 |
Buy |
3.05 |
30,227 |
92,292 |
2,111,395 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 03 '24 |
Buy |
3.55 |
166,042 |
589,565 |
1,648,577 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 11 '24 |
Buy |
3.45 |
94,537 |
326,304 |
1,891,312 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 10 '24 |
Buy |
3.46 |
55,463 |
192,130 |
1,796,775 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 08 '24 |
Buy |
3.46 |
47,492 |
164,190 |
1,724,395 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 05 '24 |
Buy |
3.43 |
28,326 |
97,065 |
1,676,903 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 09 '24 |
Buy |
3.43 |
16,917 |
58,091 |
1,741,312 |
2.02%
0.47%
자본화:
|
볼륨(24시간):